Pembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis
2024

Comparing Pembrolizumab and Sintilimab for Advanced Lung Cancer

Sample size: 225 publication 10 minutes Evidence: moderate

Author Information

Author(s): Xia Zhengzheng, Hong Juan, Yu Xiangyang, Ran Yuhua, Xie Huali, Zhou Ziyuan, Zuo Jing, Chen Tujia, Meng Jun, Yang Jun

Primary Institution: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Hypothesis

Do pembrolizumab and sintilimab have significantly different effects on patients with advanced non-small cell lung cancer (NSCLC)?

Conclusion

Sintilimab and pembrolizumab show similar effectiveness in treating advanced NSCLC, but sintilimab may have a better safety profile.

Supporting Evidence

  • Median progression-free survival was 8.68 months for sintilimab and 9.46 months for pembrolizumab.
  • Objective response rate was 30.2% for pembrolizumab and 41.3% for sintilimab.
  • Disease control rate was 84.1% for pembrolizumab and 88.9% for sintilimab.
  • Grade 3 or 4 treatment-related adverse events were higher in the pembrolizumab group (42.9%) compared to sintilimab (33.3%).

Takeaway

This study looked at two cancer treatments and found that they work about the same, but one might be safer than the other.

Methodology

A retrospective multicenter cohort study with propensity-score matching analysis comparing the effectiveness and safety of pembrolizumab and sintilimab.

Potential Biases

Potential biases due to unmeasured confounders like baseline health status and lifestyle factors.

Limitations

The study is retrospective, and unobserved factors may have influenced outcomes; it also involved only Chinese patients from two hospitals.

Participant Demographics

Patients aged 18 to 90 years with advanced NSCLC, including both male and female participants.

Statistical Information

P-Value

0.043

Confidence Interval

95% CI 0.466–1.583

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fonc.2024.1422039

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication